WebNov 14, 2024 · In October, Cullinan Oncology announced that it increased its ownership in its Cullinan MICA Corp. (MICA) subsidiary, which holds the worldwide rights to CLN-619. Ownership increased from 54%... WebMar 14, 2024 · Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most...
Targeted Therapies 101
WebCullinan Oncology is dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, … WebJul 25, 2024 · DISCLOSURE: Dr. Yu has served as a consultant or advisor to AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo, and Janssen; has received institutional research funding from Astellas Pharma, AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, … sarah threlfall
Cullinan bags $150M to build broad slate of cancer assets
WebOptical Coherence Tomography News Feb 5 2024 Neurology , Funding Georgia Institute of Technology Receives a 2024 NIH Grant for $182,900 for Stimulated Raman Scattering … WebJun 4, 2024 · June 04, 2024 10:00 AM Eastern Daylight Time CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Cullinan Oncology, LLC announced today the closing of a $98.5 … WebOct 3, 2024 · Cullinan Oncology has raised $150 million to build a portfolio of cancer R&D programs. Cullinan Oncology has raised $150 million to build a portfolio of cancer R&D programs. The idea is to ... shot arrow